Literature DB >> 21622262

C-type lectins in immunity to Mycobacterium tuberculosis.

Antoine Tanne1, Olivier Neyrolles.   

Abstract

Tuberculosis (TB) remains one of the leading causes of death due to a single infectious agent, Mycobacterium tuberculosis, with nearly 2 million deaths per year (1). Most individuals exposed to the bacillus develop a nonpathological form, latent TB, with only a small minority (5 to 10%) developing active disease. It is estimated that one third of the human population worldwide may have latent M. tuberculosis infection. Latent TB is characterized by an efficient immune response that contains the infection in a nonpathological and noncontagious state, within a specific, dynamic structure called the granuloma. Interactions between M. tuberculosis and the immune system play a crucial role in determining the outcome of the disease, and are mediated by various pattern recognition receptors (PRRs) expressed in cells of the innate immune system and in nonimmune cells. These interactions may modulate the immune response in favor of the bacillus, by allowing it to persist within host phagocytes. They may also favor the host, by inducing immune defenses, such as autophagy, phagosome maturation, apoptosis and various bactericidal mechanisms.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21622262     DOI: 10.2741/217

Source DB:  PubMed          Journal:  Front Biosci (Schol Ed)        ISSN: 1945-0516


  2 in total

1.  Inherited variation in pattern recognition receptors and cancer: dangerous liaisons?

Authors:  Anton G Kutikhin; Arseniy E Yuzhalin
Journal:  Cancer Manag Res       Date:  2012-02-16       Impact factor: 3.989

Review 2.  Purification and proteomics of pathogen-modified vacuoles and membranes.

Authors:  Jo-Ana Herweg; Nicole Hansmeier; Andreas Otto; Anna C Geffken; Prema Subbarayal; Bhupesh K Prusty; Dörte Becher; Michael Hensel; Ulrich E Schaible; Thomas Rudel; Hubert Hilbi
Journal:  Front Cell Infect Microbiol       Date:  2015-06-02       Impact factor: 5.293

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.